DelMar Pharmaceuticals Inc (NASDAQ:DMPI) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.
Analysts have set a 12 month consensus price objective of $4.00 for the company and are expecting that the company will post ($0.30) earnings per share for the current quarter, according to Zacks. Zacks has also assigned DelMar Pharmaceuticals an industry rank of 87 out of 256 based on the ratings given to its competitors.
A number of research analysts have recently weighed in on the stock. Dawson James reissued a “buy” rating on shares of DelMar Pharmaceuticals in a research report on Thursday, July 11th. ValuEngine downgraded shares of Zumiez from a “hold” rating to a “sell” rating in a research report on Tuesday, July 2nd.
A hedge fund recently raised its stake in DelMar Pharmaceuticals stock. Virtu Financial LLC grew its stake in shares of DelMar Pharmaceuticals Inc (NASDAQ:DMPI) by 99.7% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 98,554 shares of the company’s stock after acquiring an additional 49,200 shares during the period. Virtu Financial LLC owned about 0.39% of DelMar Pharmaceuticals worth $48,000 at the end of the most recent reporting period. 7.85% of the stock is currently owned by institutional investors.
Shares of DMPI stock traded down $0.01 during trading hours on Friday, reaching $1.34. The company had a trading volume of 1,000 shares, compared to its average volume of 176,588. DelMar Pharmaceuticals has a twelve month low of $1.18 and a twelve month high of $8.50. The stock has a market capitalization of $3.58 million, a P/E ratio of -0.24 and a beta of 0.84. The company’s fifty day simple moving average is $1.68.
DelMar Pharmaceuticals (NASDAQ:DMPI) last posted its quarterly earnings results on Wednesday, May 15th. The company reported ($0.67) earnings per share for the quarter.
About DelMar Pharmaceuticals
DelMar Pharmaceuticals, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a DNA-targeting agent, which is in Phase II clinical study for the treatment of glioblastoma multiforme (GBM), as well as other solid tumors, including ovarian cancer.
Featured Story: How Do You Calculate Return on Investment (ROI)?
Get a free copy of the Zacks research report on DelMar Pharmaceuticals (DMPI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.